[{"orgOrder":0,"company":"Zura Bio","sponsor":"Deep Track Capital","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Private Placement","leadProduct":"Tibulizumab","moa":"IL-17 receptor\/BAFF receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Zura Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zura Bio \/ Deep Track Capital","highestDevelopmentStatusID":"6","companyTruncated":"Zura Bio \/ Deep Track Capital"},{"orgOrder":0,"company":"Agility Life Sciences","sponsor":"Conduit Pharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2025","type":"Partnership","leadProduct":"CDT1656","moa":"Glucokinase","graph1":"Immunology","graph2":"Phase I","graph3":"Agility Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Agility Life Sciences \/ Conduit Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Agility Life Sciences \/ Conduit Pharma"},{"orgOrder":0,"company":"MiroBio","sponsor":"Medicxi","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Series B Financing","leadProduct":"MB272","moa":"BTLA","graph1":"Immunology","graph2":"Phase I","graph3":"MiroBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MiroBio \/ Medicxi","highestDevelopmentStatusID":"6","companyTruncated":"MiroBio \/ Medicxi"},{"orgOrder":0,"company":"MiroBio","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Acquisition","leadProduct":"MB272","moa":"BTLA","graph1":"Immunology","graph2":"Phase I","graph3":"MiroBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MiroBio \/ Gilead Sciences","highestDevelopmentStatusID":"6","companyTruncated":"MiroBio \/ Gilead Sciences"},{"orgOrder":0,"company":"MiroBio","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Acquisition","leadProduct":"MB272","moa":"BTLA","graph1":"Immunology","graph2":"Phase I","graph3":"MiroBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MiroBio \/ Gilead Sciences","highestDevelopmentStatusID":"6","companyTruncated":"MiroBio \/ Gilead Sciences"},{"orgOrder":0,"company":"MiroBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"MB272","moa":"BTLA","graph1":"Immunology","graph2":"Phase I","graph3":"MiroBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MiroBio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MiroBio \/ Inapplicable"},{"orgOrder":0,"company":"BenevolentAI","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BEN-8744","moa":"PDE10","graph1":"Immunology","graph2":"Phase I","graph3":"BenevolentAI","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BenevolentAI \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BenevolentAI \/ Inapplicable"},{"orgOrder":0,"company":"BenevolentAI","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BEN-8744","moa":"PDE10","graph1":"Immunology","graph2":"Phase I","graph3":"BenevolentAI","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BenevolentAI \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BenevolentAI \/ Inapplicable"},{"orgOrder":0,"company":"BenevolentAI","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"BEN-8744","moa":"PDE10","graph1":"Immunology","graph2":"Phase I","graph3":"BenevolentAI","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BenevolentAI \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BenevolentAI \/ Inapplicable"},{"orgOrder":0,"company":"Microbiotica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Probiotic","year":"2025","type":"Inapplicable","leadProduct":"MB310","moa":"Gut microbiome","graph1":"Immunology","graph2":"Phase I","graph3":"Microbiotica","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Microbiotica \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Microbiotica \/ Inapplicable"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Foralumab","moa":"CD3","graph1":"Immunology","graph2":"Phase I","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tiziana Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tiziana Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Foralumab","moa":"CD3","graph1":"Immunology","graph2":"Phase I","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tiziana Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tiziana Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Thinkequity","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Public Offering","leadProduct":"Foralumab","moa":"CD3","graph1":"Immunology","graph2":"Phase I","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tiziana Life Sciences \/ Thinkequity","highestDevelopmentStatusID":"6","companyTruncated":"Tiziana Life Sciences \/ Thinkequity"},{"orgOrder":0,"company":"Kynos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"KNS366","moa":"KMO","graph1":"Immunology","graph2":"Phase I","graph3":"Kynos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kynos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kynos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NodThera","sponsor":"Organovo Holdings","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Series B Financing","leadProduct":"NT-0167","moa":"NLRP3","graph1":"Immunology","graph2":"Phase I","graph3":"NodThera","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NodThera \/ Organovo Holdings","highestDevelopmentStatusID":"6","companyTruncated":"NodThera \/ Organovo Holdings"},{"orgOrder":0,"company":"Oxford Biomedica","sponsor":"Kyverna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2023","type":"Licensing Agreement","leadProduct":"KYV-101","moa":"CD19","graph1":"Immunology","graph2":"Phase I","graph3":"Oxford Biomedica","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oxford Biomedica \/ Kyverna Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Oxford Biomedica \/ Kyverna Therapeutics"},{"orgOrder":0,"company":"Zura Bio","sponsor":"Access Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Private Placement","leadProduct":"Tibulizumab","moa":"IL-17 receptor\/BAFF receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Zura Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zura Bio \/ Access Biotechnology","highestDevelopmentStatusID":"6","companyTruncated":"Zura Bio \/ Access Biotechnology"},{"orgOrder":0,"company":"Zura Bio","sponsor":"Deep Track Capital","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Private Placement","leadProduct":"Tibulizumab","moa":"IL-17 receptor\/BAFF receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Zura Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zura Bio \/ Deep Track Capital","highestDevelopmentStatusID":"6","companyTruncated":"Zura Bio \/ Deep Track Capital"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : MB310 is an oral live biotherapeutic product which is currently being evaluated for the treatment of patients with active, mild-to-moderate ulcerative colitis.

                          Product Name : MB310

                          Product Type : Probiotic

                          Upfront Cash : Inapplicable

                          February 21, 2025

                          Lead Product(s) : MB310

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : The partnership aims to develop new solid oral-dosage form products of its autoimmune pipeline for use in future clinical trials, which includes CDT1656 for treating autoimmune diseases.

                          Product Name : CDT1656

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          January 22, 2025

                          Lead Product(s) : CDT1656

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase I

                          Sponsor : Conduit Pharma

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          03

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : KNS366 is a first-in-class small molecule kynurenine 3-monooxygenase (KMO) inhibitor, which is being evaluated for the treatment of acute and chronic inflammation.

                          Product Name : KNS366

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          April 22, 2024

                          Lead Product(s) : KNS366

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : Net proceeds will accelerate development of ZB-106 (tibulizumab), including a planned Phase 2 trial in systemic sclerosis and another evaluating its use for hidradenitis suppurativa.

                          Product Name : ZB-106

                          Product Type : Antibody

                          Upfront Cash : Undisclosed

                          April 18, 2024

                          Lead Product(s) : Tibulizumab

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase I

                          Sponsor : Access Biotechnology

                          Deal Size : $112.5 million

                          Deal Type : Private Placement

                          blank

                          05

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : BEN-8744 is an orally administered, peripherally-restricted PDE10 inhibitor, which is being developed as a potential first-in-class treatment for patients with moderate to severe ulcerative colitis.

                          Product Name : BEN-8744

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          March 25, 2024

                          Lead Product(s) : BEN-8744

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : Under the agreement, Kyverna gains access to LentiVector® platform, the first commercially approved lentiviral-based gene delivery system, to use with any Kyverna product, including its anti-CD19 CAR T-cell therapies, KYV-101 and KYV-201 which specifica...

                          Product Name : KYV-101

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          September 20, 2023

                          Lead Product(s) : KYV-101

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase I

                          Sponsor : Kyverna Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          07

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : BEN-8744 is a peripherally restricted small molecule and derived from the Benevolent PlatformTM and is a potential first-in-class PDE10 inhibitor for the treatment of Ulcerative Colitis.

                          Product Name : BEN-8744

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          August 31, 2023

                          Lead Product(s) : BEN-8744

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : The funding will allow Zura Bio to initiate a Phase 2 clinical trial for ZB-106 (tibulizumab), a potential first-in-class anti-IL-17 and anti-BAFF dual antagonist, in systemic sclerosis (SSc), followed by a Phase 2 clinical trial in hidradenitis suppurat...

                          Product Name : ZB-106

                          Product Type : Antibody

                          Upfront Cash : Undisclosed

                          June 06, 2023

                          Lead Product(s) : Tibulizumab

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase I

                          Sponsor : Deep Track Capital

                          Deal Size : $80.0 million

                          Deal Type : Private Placement

                          blank

                          09

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : The net proceedings will be used to to initiate a Phase 2 study for ZB-106 (tibulizumab), a potential first-in-class, anti-IL-17 and anti-BAFF dual antagonist, in Systemic Sclerosis.

                          Product Name : ZB-106

                          Product Type : Antibody

                          Upfront Cash : $80.0 million

                          April 27, 2023

                          Lead Product(s) : Tibulizumab

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase I

                          Sponsor : Deep Track Capital

                          Deal Size : $80.0 million

                          Deal Type : Private Placement

                          blank

                          10

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : The acquisition provides Gilead with MiroBio’s proprietary discovery platform and entire portfolio of immune inhibitory receptor agonists. MiroBio’s lead MB272, is a selective agonist of immune inhibitory receptor B and T-Lymphocyte Attenuator.

                          Product Name : MB272

                          Product Type : Antibody

                          Upfront Cash : $405.0 million

                          September 20, 2022

                          Lead Product(s) : MB272

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase I

                          Sponsor : Gilead Sciences

                          Deal Size : $405.0 million

                          Deal Type : Acquisition

                          blank